Bellerophon skyrockets as FDA allows emergency use of therapy for coronavirus

Bellerophon Therapeutics

20/03/2020 13:09

** Shares of Bellerophon Therapeutics  BLPH.O  surge more
than sixfold to $21 premarket - set for their biggest intraday
jump 
    ** Stock is top gainer across U.S. exchanges
    ** FDA allows emergency use of co's nitric oxide delivery
system, INOpulse, for COVID-19 treatment 
    ** Early studies have shown that nitric oxide inhibits the
replication of severe acute respiratory syndrome-related
coronavirus and improves survival for infected cells
    ** INOpulse is designed to treat patients in the outpatient
setting, which may be critical in helping combat further spread
of the virus and alleviate the mounting impact on hospitals - co
    ** Drugmaker Mallinckrodt  MNK.N  said last week it was
evaluating the role of inhaled nitric oxide on treating lung
complications related to COVID-19  urn:newsml:reuters.com:*:nL4N2B53QV
    ** MNK up 18% at $1.48
    ** Up to Thursday's close, BLPH down 35% YTD

 (Reporting by Saumya Sibi Joseph in Bengaluru)
 ((saumya.joseph@thomsonreuters.com))